Jim Cramer Analyzes Johnson & Johnson (JNJ) After Surgical Robotics Milestone

Jim Cramer highlighted Johnson & Johnson's FDA approval of its OTTAVA Robotic Surgical System as a critical factor in shifting market sentiment, finally recognizing the company as a high-tech innovator. He had been advocating for J&J as a "permit stock" to balance portfolios against volatile tech investments. The new system positions J&J to compete with surgical robotics leaders like Intuitive Surgical, leveraging its global network and offering a more conservative valuation.